Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise's third-quarter report carried outsized weight because the company has now delivered four consecutive years of revenue growth above 30%, raising the bar for every subsequent quarter. Investors have increasingly valued Axon not as a hardware maker but as a recurring-revenue software and artificial intelligence platform, so the mix between its Software & Services and Connected Devices segments was a central focus. With the stock trading at a premium valuation, even a modest top-line shortfall relative to consensus had the potential to trigger a sharp repricing, as it did. The results also offered a first clear look at how the company's fast-scaling counter-drone business, and its timing-sensitive Federal deployments, can introduce quarter-to-quarter variability into an otherwise predictable growth story.
Axon Enterprise reported third-quarter 2026 revenue of $908.6 million, up 28% year over year, but below the roughly $931 million to $936 million analysts had modeled. Software & Services revenue accelerated 43% to $437 million, driven by newer offerings including AI, real-time operations, Axon Records, and Axon 911. Connected Devices revenue rose 16% to $472 million, with Platform Solutions surging 106% to $125 million, partially offset by a 2% decline in TASER revenue.
Adjusted EPS came in at $1.72, below consensus of approximately $1.89 to $1.91. On a GAAP (generally accepted accounting principles) basis, net income was $57 million, or $0.68 per diluted share, versus a net loss of $2 million in the prior-year period. Adjusted EBITDA rose 33% to $236 million, slightly ahead of expectations. Total company gross margin declined to 56.7% from 60.1%, pressured by a greater mix of counter-drone equipment, higher memory costs, and new product categories.
Management reduced full-year 2026 revenue guidance to $3.61–$3.63 billion, roughly 30% growth, down from a prior 32%–34% range. The company attributed the change to three large Federal Dedrone deployments totaling about $130 million that are no longer expected in 2026. For the fourth quarter, Axon guided to revenue of $990 million to $1.01 billion and adjusted EBITDA of $245 million to $250 million.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Axon, it offers a structured way to surface comparable opportunities across the public safety and technology landscape.
Shares of Axon fell sharply following the release, with the stock dropping roughly 14% in after-hours trading on the revenue miss and reduced guidance. The selloff reflected a combination of factors: revenue came in below consensus for the first time in recent quarters, adjusted EPS missed estimates, and full-year guidance was cut. Investors were particularly focused on the counter-drone deployment delays, which underscore how large, hardware-heavy Federal orders can shift revenue timing between quarters. At the same time, the underlying software momentum—43% growth and AI ARR crossing $100 million—suggested the core recurring-revenue engine remains intact, leaving sentiment divided between near-term disappointment and longer-term confidence in the business model.
The most important near-term question is whether the three delayed Federal Dedrone deployments land in fiscal 2027 or slip further, since roughly $130 million of revenue now sits outside the 2026 outlook. Investors will want visibility into how the company manages the timing variability that comes with scaling a hardware-intensive counter-drone business alongside its higher-margin software operations.
Margin trends also warrant close attention. Gross margin compressed to 56.7% in the quarter, weighed down by counter-drone equipment, memory costs, and new product categories. Whether Axon can offset that mix shift through software growth and operating leverage will be a key test of profitability going forward.
Finally, watch the durability of the recurring-revenue base. Annual recurring revenue grew 40% to $1.75 billion, AI ARR surpassed $100 million, and net revenue retention held at 126%, all signs of healthy expansion within existing customers. The company's announced $1.2 billion investment in Skydio, lifting its ownership stake to 37%, adds a strategic growth lever but also introduces new integration and execution considerations. These factors will shape how investors interpret the next several quarters of results.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a clinical-stage biopharmaceutical company
Industry AerospaceDefense